Nuveen Asset Management LLC Has $12.61 Million Stock Position in Haemonetics Co. (NYSE:HAE)

Nuveen Asset Management LLC lessened its position in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 11.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 161,452 shares of the medical instruments supplier's stock after selling 19,887 shares during the period. Nuveen Asset Management LLC owned about 0.32% of Haemonetics worth $12,606,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the company. TD Waterhouse Canada Inc. bought a new stake in shares of Haemonetics in the 4th quarter worth approximately $25,000. Covestor Ltd lifted its holdings in shares of Haemonetics by 146.8% in the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock worth $58,000 after purchasing an additional 439 shares during the last quarter. Whittier Trust Co. bought a new stake in shares of Haemonetics in the 4th quarter worth approximately $62,000. Parkside Financial Bank & Trust lifted its holdings in shares of Haemonetics by 25.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after purchasing an additional 240 shares during the last quarter. Finally, AlphaQuest LLC lifted its holdings in shares of Haemonetics by 36,520.0% in the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock worth $143,000 after purchasing an additional 1,826 shares during the last quarter. Institutional investors own 99.67% of the company's stock.

Haemonetics Price Performance

Shares of HAE stock traded up $0.24 during mid-day trading on Thursday, hitting $67.85. 674,860 shares of the stock traded hands, compared to its average volume of 681,445. Haemonetics Co. has a twelve month low of $55.30 and a twelve month high of $94.99. The firm has a market cap of $3.26 billion, a price-to-earnings ratio of 26.71, a price-to-earnings-growth ratio of 1.11 and a beta of 0.32. The company's 50-day simple moving average is $63.29 and its 200-day simple moving average is $70.70. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97.

Haemonetics (NYSE:HAE - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.22 by $0.02. The business had revenue of $330.60 million for the quarter, compared to analysts' expectations of $329.38 million. Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. The company's quarterly revenue was down 3.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.90 EPS. As a group, equities research analysts expect that Haemonetics Co. will post 4.55 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on HAE shares. Wall Street Zen downgraded Haemonetics from a "buy" rating to a "hold" rating in a research note on Tuesday, May 13th. JMP Securities reaffirmed a "market outperform" rating and set a $100.00 target price on shares of Haemonetics in a research note on Tuesday, May 20th. Needham & Company LLC cut their target price on Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Barrington Research cut their target price on Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a research note on Friday, February 7th. Finally, Bank of America downgraded Haemonetics from a "neutral" rating to an "underperform" rating and cut their target price for the company from $95.00 to $68.00 in a research note on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $97.89.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.